A re-examination of data from phase III clinical trials for the new drug P1101 has revealed superior long-term effectiveness against the rare blood disease polycythemia vera (PV) that could also reduce chances of further complications, PharmaEssentia Corp (藥華醫藥) said yesterday.
Based on a recommendation from the US Food and Drug Administration (FDA), it hired a statistical consulting firm to determine whether P1101 or the interferon ropeginterferon-alfa-2b had achieved improvements in durable response rates among patients who had undergone 21 to 24 months of treatment, the company said.
It was also reanalyzing its clinical trial data as it prepares to file for market approval for P1101 in the US, it said.
The drug produced a 66.3 percent durable response rate, compared with 47.4 percent among patients in the control group treated with the chemotherapy drug hydroxyurea and other best available treatments, the company said, citing the consulting firm’s findings.
The durable response rate improved to 74.2 percent among patients who had prior treatment with hydroxyurea, compared with 32 percent of the control group, the company said.
Most notably, the re-examined data showed that patients’ durable response rate was diminished by prolonged use of hydroxyurea, leaving them at increased risk of contracting leukemia, it said.
The outcome also suggest that P1101 is a viable alternative as a first line treatment for PV patients who are on a regimen of hydroxyurea, it said.
The company is upbeat on P1101’s potential as a long-term treatment for PV, due to its ability in producing an improved 69.6 percent partial molecular response among patients who have undergone 24 months of treatment, compared with 28.6 percent among the control group.
Interferons such as P1101 could be the only therapeutic option that has potentially curative effects on PV, and patients treated with the drug have demonstrated its disease-modifying property, PharmaEssentia has previously said.
Patients had shown reduced allele burden from the JAK2 gene mutation, which has been found to be directly linked to PV, the company said.
While the severe side effects that come with other interferons have prevented patients from receiving the required dosage for effective treatment, P1101 has been proven to be more tolerable, the company said.
A fresh look
‧ The company is reanalyzing its clinical trial data on the interferon known as P1101 as it prepares to file for market approval in the US.
‧ The outcome suggests that P1101 is a viable alternative for PV patients on a regimen of hydroxyurea, the firm said.
Stephen Garrett, a 27-year-old graduate student, always thought he would study in China, but first the country’s restrictive COVID-19 policies made it nearly impossible and now he has other concerns. The cost is one deterrent, but Garrett is more worried about restrictions on academic freedom and the personal risk of being stranded in China. He is not alone. Only about 700 American students are studying at Chinese universities, down from a peak of nearly 25,000 a decade ago, while there are nearly 300,000 Chinese students at US schools. Some young Americans are discouraged from investing their time in China by what they see
MAJOR DROP: CEO Tim Cook, who is visiting Hanoi, pledged the firm was committed to Vietnam after its smartphone shipments declined 9.6% annually in the first quarter Apple Inc yesterday said it would increase spending on suppliers in Vietnam, a key production hub, as CEO Tim Cook arrived in the country for a two-day visit. The iPhone maker announced the news in a statement on its Web site, but gave no details of how much it would spend or where the money would go. Cook is expected to meet programmers, content creators and students during his visit, online newspaper VnExpress reported. The visit comes as US President Joe Biden’s administration seeks to ramp up Vietnam’s role in the global tech supply chain to reduce the US’ dependence on China. Images on
New apartments in Taiwan’s major cities are getting smaller, while old apartments are increasingly occupied by older people, many of whom live alone, government data showed. The phenomenon has to do with sharpening unaffordable property prices and an aging population, property brokers said. Apartments with one bedroom that are two years old or older have gained a noticeable presence in the nation’s six special municipalities as well as Hsinchu county and city in the past five years, Evertrust Rehouse Co (永慶房產集團) found, citing data from the government’s real-price transaction platform. In Taipei, apartments with one bedroom accounted for 19 percent of deals last
US CONSCULTANT: The US Department of Commerce’s Ursula Burns is a rarely seen US government consultant to be put forward to sit on the board, nominated as an independent director Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the world’s largest contract chipmaker, yesterday nominated 10 candidates for its new board of directors, including Ursula Burns from the US Department of Commerce. It is rare that TSMC has nominated a US government consultant to sit on its board. Burns was nominated as one of seven independent directors. She is vice chair of the department’s Advisory Council on Supply Chain Competitiveness. Burns is to stand for election at TSMC’s annual shareholders’ meeting on June 4 along with the rest of the candidates. TSMC chairman Mark Liu (劉德音) was not on the list after in December last